While the intended timely sequencing of TT5 treatment segments was accomplished at acceptable toxicities (off study rate for toxicities, 12%), clinical outcomes were similar in TT5 and predecessor trials TT3a and TT3b, with a strong trend for inferiority for complete response durations despite comparable CR kinetics.
← all excerpts
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
1
—
—